Literature DB >> 11390415

Gene therapy for rheumatoid arthritis?

M Feldmann1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390415      PMCID: PMC209327          DOI: 10.1172/JCI13209

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  4 in total

1.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis.

Authors:  A Nakajima; C M Seroogy; M R Sandora; I H Tarner; G L Costa; C Taylor-Edwards; M H Bachmann; C H Contag; C G Fathman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  Clinical trials in the gene therapy of arthritis.

Authors:  C H Evans; S C Ghivizzani; J H Herndon; M C Wasko; J Reinecke; P Wehling; P D Robbins
Journal:  Clin Orthop Relat Res       Date:  2000-10       Impact factor: 4.176

  4 in total
  1 in total

Review 1.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.